GlassScriptPhysician profile
David Quarles
NPI 1235436577
$4,935.81
in general payments reported to CMS, 2019-2025
24 companies · $1,049 in 2025
The $1,049 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $144 · 2022: $496 · 2023: $533 · 2024: $2,713 · 2025: $1,049.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,531 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,620 · Consulting Fee: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,530.79 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,620.00 |
| Consulting Fee | $144.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $2,421.33 | 2024-2025 | Rezdiffra, Resmetirom |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $643.75 | 2021-2024 | Xifaxan, Trulance, Plenvu |
| Phathom Pharmaceuticals, INC. | $293.54 | 2023-2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $261.92 | 2024 | Zeposia |
| Abbvie INC. | $215.45 | 2022-2025 | |
| Ipsen Biopharmaceuticals, INC | $178.66 | 2025 | Iqirvo |
| Merck Sharp & Dohme LLC | $126.98 | 2021-2024 | Dificid |
| Intercept Pharmaceuticals, INC. | $122.83 | 2022-2025 | Ocaliva |
| Takeda Pharmaceuticals U.S.A., INC. | $100.81 | 2022-2025 | Entyvio |
| Ardelyx, INC. | $67.30 | 2023-2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $61.36 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $58.48 | 2022-2025 | Dupixent |
| Aimmune Therapeutics, INC. | $58.10 | 2024-2025 | Vowst |
| Braintree Laboratories, INC. | $50.94 | 2022 | |
| Fujifilm Healthcare Americas Corporation | $47.04 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $45.37 | 2023-2024 | Linzess |
| Novo Nordisk INC | $34.32 | 2025 | Wegovy, Saxenda |
| Ferring Pharmaceuticals INC. | $26.44 | 2022-2023 | Rebyota |
| Qol Medical, LLC | $22.88 | 2025 | Sucraid |
| Orphalan INC | $21.98 | 2025 | Cuvrior |
| Genzyme Corporation | $21.54 | 2025 | |
| Daiichi Sankyo INC. | $21.48 | 2024 | Injectafer |
| Evoke Pharma, INC. | $20.46 | 2023 | Gimoti |
| Redhill Biopharma INC. | $12.85 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Quarles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.